DR REDDYS LABORATORIES
|
DR REDDYS LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 270.55 | 131.16 | 117.28 | 121.90 | 117.47 |
| CEPS(Rs) | 345.59 | 201.18 | 191.13 | 191.88 | 185.83 |
| DPS(Rs) | 40.00 | 30.00 | 25.00 | 25.00 | 20.00 |
| Book NAV/Share(Rs) | 1,388.98 | 1,145.98 | 1,052.59 | 932.31 | 840.01 |
| Tax Rate(%) | 25.48 | 28.71 | 32.32 | -7.44 | 16.52 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 25.74 | 17.49 | 20.32 | 14.10 | 20.57 |
| EBIT Margin(%) | 25.10 | 14.65 | 15.65 | 11.33 | 15.70 |
| Pre Tax Margin(%) | 24.52 | 14.21 | 15.14 | 10.76 | 15.12 |
| PAT Margin (%) | 18.27 | 10.13 | 10.25 | 11.57 | 12.62 |
| Cash Profit Margin (%) | 23.34 | 15.54 | 16.70 | 18.21 | 19.97 |
| Performance Ratios | |||||
| ROA(%) | 15.01 | 8.08 | 8.21 | 9.20 | 8.86 |
| ROE(%) | 21.36 | 11.93 | 11.82 | 13.76 | 14.75 |
| ROCE(%) | 26.22 | 14.59 | 15.49 | 11.12 | 13.66 |
| Asset Turnover(x) | 0.82 | 0.80 | 0.80 | 0.80 | 0.70 |
| Sales/Fixed Asset(x) | 1.01 | 0.96 | 0.92 | 0.94 | 0.87 |
| Working Capital/Sales(x) | 2.10 | 2.69 | 2.96 | 3.25 | 2.96 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.99 | 1.04 | 1.08 | 1.07 | 1.15 |
| Receivable days | 103.01 | 98.60 | 95.74 | 93.92 | 94.98 |
| Inventory Days | 73.65 | 81.57 | 77.11 | 71.52 | 74.03 |
| Payable days | 108.07 | 99.98 | 100.14 | 95.02 | 109.69 |
| Valuation Parameters | |||||
| PER(x) | 17.08 | 32.83 | 38.50 | 25.57 | 23.62 |
| PCE(x) | 13.37 | 21.40 | 23.63 | 16.24 | 14.93 |
| Price/Book(x) | 3.33 | 3.76 | 4.29 | 3.34 | 3.30 |
| Yield(%) | 0.87 | 0.70 | 0.55 | 0.80 | 0.72 |
| EV/Net Sales(x) | 3.11 | 3.37 | 3.99 | 3.07 | 3.22 |
| EV/Core EBITDA(x) | 10.35 | 17.08 | 18.29 | 17.41 | 14.13 |
| EV/EBIT(x) | 12.37 | 23.00 | 25.53 | 27.12 | 20.48 |
| EV/CE(x) | 2.43 | 2.55 | 2.98 | 2.45 | 2.25 |
| M Cap / Sales | 3.12 | 3.33 | 3.94 | 2.96 | 2.98 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 14.50 | 13.11 | 8.74 | 13.39 | 8.17 |
| Core EBITDA Growth(%) | 74.14 | 2.18 | 34.63 | -12.08 | 40.27 |
| EBIT Growth(%) | 96.10 | 5.93 | 50.23 | -18.18 | 69.65 |
| PAT Growth(%) | 106.52 | 11.83 | -3.67 | 3.90 | 113.72 |
| EPS Growth(%) | 106.27 | 11.83 | -3.79 | 3.77 | 105.96 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.06 | 0.18 | 0.17 | 0.14 | 0.28 |
| Current Ratio(x) | 2.37 | 1.82 | 1.79 | 1.75 | 1.88 |
| Quick Ratio(x) | 1.80 | 1.30 | 1.23 | 1.26 | 1.31 |
| Interest Cover(x) | 43.36 | 32.96 | 30.73 | 20.18 | 27.27 |
| Total Debt/Mcap(x) | 0.02 | 0.05 | 0.04 | 0.04 | 0.08 |
Compare Financial Ratios of peers of DR REDDYS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DR REDDYS LABORATORIES | ₹96,731.5 Cr | -2% | -4.2% | 29.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹367,470.0 Cr | 0.4% | -0.4% | 61.2% | Stock Analytics | |
| CIPLA | ₹112,990.0 Cr | -1.1% | 1.7% | 53.9% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹105,846.0 Cr | 5.9% | 11.3% | 94.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹103,849.0 Cr | -0.1% | 3.9% | 20% | Stock Analytics | |
| MANKIND PHARMA | ₹83,873.0 Cr | -4% | -8.3% | 51.1% | Stock Analytics | |
DR REDDYS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DR REDDYS LABORATORIES | -2% |
-4.2% |
29.3% |
| SENSEX | 1.7% |
0.7% |
19.2% |
You may also like the below Video Courses
